Cargando…

Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan

BACKGROUND/AIMS: Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk profile of anti-TNF and thiopurines during pregnancy in Asia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komoto, Shunsuke, Motoya, Satoshi, Nishiwaki, Yuji, Matsui, Toshiyuki, Kunisaki, Reiko, Matsuoka, Katsuyoshi, Yoshimura, Naoki, Kagaya, Takashi, Naganuma, Makoto, Hida, Nobuyuki, Watanabe, Mamoru, Hibi, Toshifumi, Suzuki, Yasuo, Miura, Soichiro, Hokari, Ryota
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association for the Study of Intestinal Diseases 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863047/ https://www.ncbi.nlm.nih.gov/pubmed/27175114 http://dx.doi.org/10.5217/ir.2016.14.2.139

Ejemplares similares

Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2018)

Endoscopic and clinical evaluation of treatment and prognosis of Cronkhite–Canada syndrome: a Japanese nationwide survey
por: Watanabe, Chikako, et al.
Publicado: (2015)

Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan
por: Ueno, Fumiaki, et al.
Publicado: (2012)

NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
por: Matsuoka, Katsuyoshi
Publicado: (2020)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries
por: Kobayashi, Taku, et al.
Publicado: (2018)

Evidence-based clinical practice guidelines for inflammatory bowel disease
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2018)

An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn’s disease
por: Yoshimura, Naoki, et al.
Publicado: (2015)

Endoscopic and Pathologic Changes of the Upper Gastrointestinal Tract in Crohn's Disease
por: Sakuraba, Atsushi, et al.
Publicado: (2014)

Modulation by luminal factors on the functions and migration of intestinal innate immunity
por: Higashiyama, Masaaki, et al.
Publicado: (2023)

Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
por: Motoya, Satoshi, et al.
Publicado: (2019)

Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study
por: Motoya, Satoshi, et al.
Publicado: (2019)

Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
por: Watanabe, Kenji, et al.
Publicado: (2019)

Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2019)

Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy
por: Hata, Keisuke, et al.
Publicado: (2020)

Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network)
por: Yamazaki, Hajime, et al.
Publicado: (2019)

Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis
por: Kobayashi, Taku, et al.
Publicado: (2020)

Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy
por: Takayama, Tetsuro, et al.
Publicado: (2015)

NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study
por: Kakuta, Yoichi, et al.
Publicado: (2018)

Pharmacogenetics of thiopurine therapy: from thiopurine S-methyltransferase to S-adenosylmethionine
por: Mlinarič-Raščan, Irena, et al.
Publicado: (2009)

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
por: Hisamatsu, Tadakazu, et al.
Publicado: (2021)

Prevalence of serum celiac antibody in patients with IBD in Japan
por: Watanabe, Chikako, et al.
Publicado: (2013)

NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
por: Sato, Toshiyuki, et al.
Publicado: (2017)

Pharmacogenetics of thiopurines
por: Franca, Raffaella, et al.
Publicado: (2019)

Thiopurine Methyltransferase Activity and Thiopurine Metabolites in Inflammatory Bowel Disease
por: El-Matary, Wael
Publicado: (2020)

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
por: Kobayashi, Taku, et al.
Publicado: (2015)

Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2021)

Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?
por: Gargallo-Puyuelo, Carla J., et al.
Publicado: (2021)

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial
por: Hisamatsu, Tadakazu, et al.
Publicado: (2018)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
por: Hibi, Toshifumi, et al.
Publicado: (2023)

Evaluation by MR Enterocolonography of Lansoprazole-induced Collagenous Colitis Accompanied with Protein-losing Enteropathy
por: Mizoguchi, Akinori, et al.
Publicado: (2017)

Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose
por: Yin, Dandan, et al.
Publicado: (2017)

Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2023)

Hepatic portal venous gas and bacteremia after colonic endoscopic submucosal dissection: A case report
por: Tomioka, Akira, et al.
Publicado: (2022)

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease
por: Ogata, Haruhiko, et al.
Publicado: (2016)

Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
por: Hibi, Toshifumi, et al.
Publicado: (2020)

Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease
por: Gazouli, Μaria, et al.
Publicado: (2012)

Pharmacogenetic studies of thiopurine methyltransferase genotype‐phenotype concordance and effect of methotrexate on thiopurine metabolism
por: Zimdahl Kahlin, Anna, et al.
Publicado: (2020)

Assessment of Thiopurine–based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia
por: Azimi, F, et al.
Publicado: (2014)

Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics
por: Lennard, Lynne, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qske3ftvnea4fm09jgb8pteacd